LENZ Therapeutics (LENZ) Receivables (2025 - 2026)
LENZ Therapeutics' (LENZ) quarterly Receivables came in at $343000.0 in Q1 2026, up 4.26% on a QoQ basis from $329000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Receivables (2025 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of Receivables data on file, last reported at $343000.0 in Q1 2026.
- On a quarterly basis, Receivables changed N/A year-over-year to $343000.0 in Q1 2026; TTM through Mar 2026 was $343000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $329000.0, changed N/A from the prior year.
- Receivables for Q1 2026 stood at $343000.0, up from $329000.0 in the prior quarter.
- Over the last five years, Receivables for LENZ reached as high as $343000.0 in Q1 2026 and fell as low as $329000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | LENZ Therapeutics | 158.34 Mn | 158.34 Mn | 825,000.00 | 343,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 343,000.00 |
| Dec 31, 2025 | 329,000.00 |